Market Focus: Royal Caribbean Cruises Ltd. (NYSE:RCL), Teva Pharmaceutical Industries Limited (NYSE:TEVA) Valuation Review & Update

Royal Caribbean Cruises Ltd. (NYSE:RCL) has an ERP5 rank of 9179. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies.  The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC.  The lower the ERP5 rank, the more undervalued a company is thought to be.

When it comes to investing, people are generally told to make sure that they don’t put all their eggs in one basket. This saying can apply to investing in the stock market as well. Keeping the stock portfolio diversified can greatly behoove the individual investor. When hard earned money is on the line, individuals may want to pay extra attention as to how their equity holdings are spread out. Many investors will choose to pick stocks that combine large cap, small cap, and even international stocks. Although stock portfolio diversification does not eliminate risk, it can help reduce it during tumultuous market conditions.

The Q.i. Value of Royal Caribbean Cruises Ltd. (NYSE:RCL) is 36.00000. The Q.i. Value is another helpful tool in determining if a company is undervalued or not. The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the company is thought to be.

Technicals
The EBITDA Yield is a great way to determine a company’s profitability. This number is calculated by dividing a company’s earnings before interest, taxes, depreciation and amortization by the company’s enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The EBITDA Yield for Royal Caribbean Cruises Ltd. (NYSE:RCL) is 0.081720.

The Earnings to Price yield of Royal Caribbean Cruises Ltd. (NYSE:RCL) is 0.071042.  This is calculated by taking the earnings per share and dividing it by the last closing share price.  This is one of the most popular methods investors use to evaluate a company’s financial performance.  Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company.  The Earnings Yield for Royal Caribbean Cruises Ltd. (NYSE:RCL) is 0.052813.  Earnings Yield helps investors measure the return on investment for a given company.  Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value.  The Earnings Yield Five Year average for Royal Caribbean Cruises Ltd. is 0.033684.

The FCF Yield 5yr Average is calculated by taking the five year average free cash flow of a company, and dividing it by the current enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The average FCF of a company is determined by looking at the cash generated by operations of the company. The Free Cash Flow Yield 5 Year Average of Royal Caribbean Cruises Ltd. (NYSE:RCL) is 0.017286.

Ratios

The Current Ratio of Royal Caribbean Cruises Ltd. (NYSE:RCL) is 0.16. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. The current ratio looks at all the liquid and non-liquid assets compared to the company’s total current liabilities. A high current ratio indicates that the company might have trouble managing their working capital. A low current ratio (when the current liabilities are higher than the current assets) indicates that the company may have trouble paying their short term obligations.

The Leverage Ratio of Royal Caribbean Cruises Ltd. (NYSE:RCL) is 0.420624.  Leverage ratio is the total debt of a company divided by total assets of the current and past year divided by two.  Companies take on debt to finance their day to day operations.  The leverage ratio can measure how much of a company’s capital comes from debt.  With this ratio, investors can better estimate how well a company will be able to pay their long and short term financial obligations.

The price to book ratio or market to book ratio for Royal Caribbean Cruises Ltd. (NYSE:RCL) currently stands at 2.300921.  The ratio is calculated by dividing the stock price per share by the book value per share.  This ratio is used to determine how the market values the equity.  A ratio of under 1 typically indicates that the shares are undervalued.  A ratio over 1 indicates that the market is willing to pay more for the shares.  There are often many underlying factors that come into play with the Price to Book ratio so all additional metrics should be considered as well. 

Adding it All Up

The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength.  The score helps determine if a company’s stock is valuable or not.  The Piotroski F-Score of Royal Caribbean Cruises Ltd. (NYSE:RCL) is 7.  A score of nine indicates a high value stock, while a score of one indicates a low value stock.  The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings.  It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue.  The score is also determined by change in gross margin and change in asset turnover.

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of Royal Caribbean Cruises Ltd. (NYSE:RCL) is 14.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.

Accumulating knowledge about the stock market can be a big part of the investment planning process. Proper allocation of equity investments is also an important factor. Finding the proper mix of stocks may end up being more important than the single stocks added to the portfolio. Determining the correct asset allocation can depend on variables such as risk appetite and financial goals. These goals may be short-term, medium term, or longer-term. Investors will often have to determine how aggressive they will be when buying stocks. This can also depend on the overall time horizon and risk tolerance. Some investors might be unfazed by continuous market fluctuations. Others may be much more sensitive, and they may need to adjust their plans accordingly.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has an ERP5 rank of 709. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies.  It looks at the stock’s Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC.  The lower the rank, the more undervalued a company is considered to be.

As many veteran investors have already seen, market movements are extremely hard to accurately predict. Financial news outlets are always producing headlines and offering predictions for future market performance. Sometimes the predictions are right, and sometimes the predictions are wrong. Investors may have a hard time separating fact from fiction when it comes to bullish and bearish sentiment. Adjusting the portfolio based strictly on headlines can be tempting for the amateur investor. Filtering out the noise and focusing on the pertinent data can help keep the individual focused and on track. Straying from the plan and basing investment decisions on news headlines may lead to portfolio confusion down the road. Crunching the numbers and paying attention to the important economic data can greatly help the investor see through the smoke when markets get muddled.

The Q.i. Value of Teva Pharmaceutical Industries Limited (NYSE:TEVA) is 34.00000. The Q.i. Value is another helpful tool in determining if a company is undervalued or not. The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the company is thought to be.

The EBITDA Yield is a great way to determine a company’s profitability. This number is calculated by dividing a company’s earnings before interest, taxes, depreciation and amortization by the company’s enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The EBITDA Yield for Teva Pharmaceutical Industries Limited (NYSE:TEVA) is 0.105968.

The Earnings to Price yield of Teva Pharmaceutical Industries Limited (NYSE:TEVA) is -0.299703.  This is calculated by taking the earnings per share and dividing it by the last closing share price.  This is one of the most popular methods investors use to evaluate a company’s financial performance.  Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company.  The Earnings Yield for Teva Pharmaceutical Industries Limited (NYSE:TEVA) is 0.063761.  Earnings Yield helps investors measure the return on investment for a given company.  Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value.  The Earnings Yield Five Year average for Teva Pharmaceutical Industries Limited is 0.106195.

The FCF Yield 5yr Average is calculated by taking the five year average free cash flow of a company, and dividing it by the current enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The average FCF of a company is determined by looking at the cash generated by operations of the company. The Free Cash Flow Yield 5 Year Average of Teva Pharmaceutical Industries Limited (NYSE:TEVA) is 0.086079.

Price Index

We can now take a quick look at some historical stock price index data. Teva Pharmaceutical Industries Limited (NYSE:TEVA) presently has a 10 month price index of 0.45807. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 0.50464, the 24 month is 0.40631, and the 36 month is 0.23463. Narrowing in a bit closer, the 5 month price index is 0.69280, the 3 month is 0.64587, and the 1 month is currently 0.69635.

Returns

Looking at some ROIC (Return on Invested Capital) numbers, Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s ROIC is 0.319420. The ROIC 5 year average is 0.446128 and the ROIC Quality ratio is 3.928890. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a firm is at turning capital into profits.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has a Price to Book ratio of 0.806074. This ratio is calculated by dividing the current share price by the book value per share. Investors may use Price to Book to display how the market portrays the value of a stock. Checking in on some other ratios, the company has a Price to Cash Flow ratio of 11.181816, and a current Price to Earnings ratio of -3.336636. The P/E ratio is one of the most common ratios used for figuring out whether a company is overvalued or undervalued.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) presently has a current ratio of 0.96. The current ratio, also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the current liabilities. The ratio is simply calculated by dividing current liabilities by current assets. The ratio may be used to provide an idea of the ability of a certain company to pay back its liabilities with assets. Typically, the higher the current ratio the better, as the company may be more capable of paying back its obligations.

The Price to book ratio is the current share price of a company divided by the book value per share.  The Price to Book ratio for Teva Pharmaceutical Industries Limited NYSE:TEVA is 0.806074.  A lower price to book ratio indicates that the stock might be undervalued.  Similarly, Price to cash flow ratio is another helpful ratio in determining a company’s value.  The Price to Cash Flow for Teva Pharmaceutical Industries Limited (NYSE:TEVA) is 11.181816.  This ratio is calculated by dividing the market value of a company by cash from operating activities.  Additionally, the price to earnings ratio is another popular way for analysts and investors to determine a company’s profitability.  The price to earnings ratio for Teva Pharmaceutical Industries Limited (NYSE:TEVA) is -3.336636. This ratio is found by taking the current share price and dividing by earnings per share.

As we move closer towards the end of the year, investors may be undertaking a portfolio review. Reviewing trades over the past six months, investors should be able to see what has worked and what has not. There might be some stocks that have outperformed the market, and there might be some underperformers as well. Focusing on what has worked so far this year may help provide a clearer picture for future moves. Pinpointing what went wrong can also help the investor see which areas of the portfolio need improvement. If the stock market continues on to reach new heights, investors might be looking to lock in some profits before making the next big trade.